评估抗逆转录病毒治疗中断期间 HIV-1 模糊核苷酸频率。
Evaluation of HIV-1 ambiguous nucleotide frequency during antiretroviral treatment interruption.
机构信息
Division of Infectious Diseases, Brigham and Women’s Hospital, 65 Landsdowne Street, Room 435, Cambridge, MA, USA.
出版信息
J Acquir Immune Defic Syndr. 2012 Sep 1;61(1):19-22. doi: 10.1097/QAI.0b013e318264460f.
Nucleotide mixtures in human immunodeficiency virus type 1 (HIV-1) population sequences reflect sequence diversity. We evaluated gag and pol ambiguous nucleotide frequencies during an analytic treatment interruption (ATI) in an HIV-1 therapeutic vaccine study. The proportion of ambiguous nucleotides was significantly higher at ATI week 16 than at either the time of first detectable viremia (P < 0.001 gag and P = 0.03 reverse transcriptase) or preantiretroviral therapy (P = 0.007 gag). No significant differences were observed in the proportion of ambiguous nucleotides between those receiving vaccine and placebo. Increased HIV diversity during the ATI may represent a potentially higher barrier to success for a therapeutic as compared with a preventative vaccine targeting cell-mediated immunity.
人类免疫缺陷病毒 1 型（HIV-1）群体序列中的核苷酸混合物反映了序列多样性。我们在 HIV-1 治疗性疫苗研究中分析性治疗中断（ATI）期间评估了 gag 和 pol 模糊核苷酸频率。在 ATI 第 16 周时，模糊核苷酸的比例明显高于首次可检测到病毒血症时（P<0.001 gag 和 P=0.03 逆转录酶）或抗逆转录病毒治疗前（P=0.007 gag）。在接受疫苗和安慰剂的患者中，模糊核苷酸的比例没有显著差异。与针对细胞介导免疫的预防性疫苗相比，ATI 期间 HIV 多样性的增加可能代表治疗性疫苗成功的潜在更高障碍。
Zotero 插件